INO IN PREMATURE NEWBORNS – SHORT AND LONG TERM OUTCOME

Authors

  • Radulova P. University Hospital of Obstetrics and Gynecology “ Maichin dom “, Sofia, Bulgaria
  • Slancheva B. University Hospital of Obstetrics and Gynecology “ Maichin dom “, Sofia, Bulgaria
  • Marinov R. National Heart Hospital, Sofia, Bulgaria

Keywords:

iNO, ELBW, Pulmonary hypertension, Bronchopulmonary dysplasia, chronic complications

Abstract

According to a rising number of randomized controlled clinical trials the “off label” usage of iNO in premature babies is rising in the last few years. Nowadays in the era of the precise medicine it is of great importance to differentiate the population of premature babies with critical hypoxic pulmonary failure that is most likely to gain positive effect from iNO treatment. The described trial compares the iNO therapy with the conventional therapy regarding the short and long term outcome in premature newborns below 30 week of gestation. A group of premature infants with specific characteristics is clearly defined, where the usage of iNO leads to positive effect concerning the outcome.

References

I. Barrington KJ, Finer N. Inhaled nitric oxide for respiratory failure in preterm infants. The Cochrane database of systematic reviews. 2010;(12):CD000509.

II. Abman SH, Hansmann G, Archer SL, et al. American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; and the American Thoracic Society. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation. 2015;132(21):2037–2099.

III. Ali Z, Schmidt P, Dodd J, Jeppesen DL. Predictors of bronchopulmonary dysplasiq and pulmonary hypertension in newborn children. Dan Med J. 2013. 60(8), A4688.

IV. Seth SA, Soraisham AS, Harabor A. Risk factors and outcome of early pulmonary hypertension in preterm infants. 2017. 21,1-6.

V. Cole FS, Alleyne C, Barks JD, et al. NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics. 2011 Feb;127(2):363–369.

VI. Kumar P. Use of inhaled nitric oxide in preterm infants. Pediatrics. 2014 Jan;133(1):164–170.

VII. Handley SCSR, Hopper AO, Govindaswami B, Bhatt DR, Van Meurs KP, Ariagno RA, Gould JB, Lee HC. Patterns of inhaled nitric oxide use in preterm infants in California Neonatal Intensive Care Units. Journal of perinatology : official journal of the California Perinatal Association. 2016.

VIII. Finer NN, Evans N. Inhaled nitric oxide for the preterm infant: evidence versus practice. Pediatrics. 2015 Apr;135(4):754–756.

IX. Ellsworth MA, Harris MN, Carey WA, Spitzer AR, Clark RH. Off-label use of inhaled nitric oxide after release of NIH Consensus Statement. Pediatrics. 2015;135(4):643–648.

X. Austin ED, Loyd JE. Toward precision medicine in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;192(11):1272–1274.

XI. Kinsella JP, Steinhorn RH, Krishnan US, et al. Recommendations for the use of inhaled nitric oxide therapy in premature newborns with severe pulmonary hypertension. J Pediatr. 2016;170:312–314.

Additional Files

Published

15-08-2020

How to Cite

Radulova P., Slancheva B., & Marinov R. (2020). INO IN PREMATURE NEWBORNS – SHORT AND LONG TERM OUTCOME. International Education and Research Journal (IERJ), 6(8). Retrieved from https://ierj.in/journal/index.php/ierj/article/view/2106